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Abstract In 2008, the World Health Organization (WHO)
published a revised and updated edition of the classification
of tumors of the hematopoietic and lymphoid tissues. The
aims of the fourth edition of the WHO classification was to
incorporate new scientific and clinical information in order
to refine diagnostic criteria for previously described neo-
plasms and to introduce newly recognized disease entities.
The recognition that T-cell lymphomas are related to the
innate and adaptive immune system, as well as enhanced
understanding of other T-cell subsets, such as the regula-
tory T-cell and follicular helper T-cells, has contributed to
our understanding of the morphologic, histologic, and
immunophenotypic features of T- and NK-cell neoplasms.
The purpose of this review is to highlight major changes in
the classification of T- and NK-cell neoplasms and to
explain the rationale for these changes.
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Introduction
The 2008 World Health Organization (WHO) classification
of mature thymus (T)- and natural killer (NK)-cell neo-
plasms provide clarification regarding diagnostic criteria,
etiologic insights, and prognostic information for several
new/provisional entities [1]. The recognition that T-cell
lymphomas are related to the innate and adaptive immune
system, as well as enhanced understanding of other T-cell
subsets, such as the regulatory T-cell and follicular helper
T-cells (TFH), has contributed to our understanding of the
morphologic, histologic, and immunophenotypic features of
T- and NK-cell neoplasms. New insights regarding immu-
nophenotypic features of large granular lymphocytes and
NK-cells have provided better flow cytometric tools for the
diagnosis of T-cell large granular lymphocytic leukemia (T-
LGL). The broad clinical spectrum of NK-cell neoplasms is
now recognized with the new provisional entity encom-
passed by chronic lymphoproliferative disorder of NK-
cells. The importance of the role of Epstein–Barr virus
(EBV) in two T-cell lymphoproliferative disorders of
childhood has resulted in the addition of systemic EBV-
positive T-cell lymphoproliferative disease of childhood
and hydroa vacciniforme-like lymphoma as new entities. In
enteropathy-associated T-cell lymphoma (EATL), two dif-
ferent types are now recognized: the classical form and the
monomorphic type. Additionally, a precursor lesion is
recognized as intraepithelial T-cell lymphoma or EATL in
situ. Subcutaneous panniculitis-like T-cell lymphoma
(SPTCL) is now considered to be a neoplasia of mature
cytotoxic αβ T-cells. In contrast to the previous WHO
classification, cases expressing the γδ T-cell receptor
(TCR) are excluded and now reclassified as primary
cutaneous γδ T-cell lymphomas. The staging system for
mycosis fungoides (MF) has been better defined. Further-
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more, the histologic and immunophenotypic heterogeneity
within the T-cell lymphomas with cutaneous presentation is
recognized in the 2008 WHO classification resulting in
several provisional entities including primary cutaneous
CD8+ aggressive lymphoma and primary cutaneous CD4+
small/medium T-cell lymphoma. Of note, blastic NK-cell
lymphoma is now considered to be a tumor derived from a
plasmacytoid dendritic cell and is included in the myeloid
neoplasms. Angioimmunoblastic T-cell lymphoma (AITL)
has emerged as a distinctive subtype of peripheral T-cell
lymphoma (PTCL) derived from follicular T helper cells.
Anaplastic lymphoma kinase (ALK)-positive and ALK-
negative cases have been separated based on clinical and
pathogenetic data.
T-cell and NK-cell neoplasms with leukemic
presentation
Mature T-cell and NK-cell neoplasms with a predominant
leukemic or disseminated clinical presentation are repre-
sented by the following entities: T-cell prolymphocytic
leukemia (T-PLL), T-LGL, chronic lymphoproliferative
disorders of NK-cells (new entity), aggressive NK-cell
leukemia, adult T-cell leukemia/lymphoma (ATLL), and
Sezary syndrome (SS; Table 1).
T-cell prolymphocytic leukemia (T-PLL)
No significant changes have been made. The 2008 WHO
classification emphasizes the role of TCL1 immunohisto-
chemistry, which may be helpful in identifying residual T-
PLL on bone marrow sections or lymph nodes after therapy.
It is important to highlight that TCL1 can be expressed in
reactive and neoplastic B-cells and other T-cell neoplasms.
T-cell large granular lymphocytic leukemia (T-LGL)
The updated 2008 WHO classification provides additional
insights into the etiology of this rare and heterogenous
disorder. T-LGL represents a clonal population of cytotoxic
effector T-cells. The frequent association with autoimmune
disorders such as rheumatoid arthritis supports the notion
that these clones arise in setting of sustained immune
stimulation. Additionally, clonal expansions of T-LGL are
observed following allogeneic bone marrow transplantation
and in association with low-grade B-cell lymphomas. These
are thought to reflect a restricted T-cell repertoire or a type
of host response.
New insights into the expression of the CD94/NKG2
and killer immunoglobulin-like receptors (KIR) families of
NK-associated major histocompatibility complex-class I
receptors in T-LGLs are provided in the updated 2008
WHO classification. More than 50% of T-LGL leukemias
express CD94/NKG2 and KIR family receptors. The
uniform expression of a single isoform of KIR can serve
as a surrogate for clonality.
Chronic lymphoproliferative disorder of NK-cells
Chronic lymphoproliferative disorder of NK-cells were
previously designated as chronic NK-cell lymphocytosis,
chronic NK-large granular lymphocyte lymphoproliferative
disorder, and NK-cell LGL lymphocytosis, all of which
reflected the variable and heterogeneous neoplastic poten-
tial of the proliferations. They are rare and are characterized
Table 1 Summary of the categories of T-cell and NK-cell neoplasms with a predominant leukemic presentation within the 2001 and 2008 WHO
classification
2001 WHO classification 2008 WHO classification Comments
T-cell prolymphocytic leukemia T-cell prolymphocytic leukemia No changes
T-cell large granular lymphocytic
leukemia
T-cell large granular lymphocytic
leukemia
New insights into etiology
New insights into the expression of the CD94/NKG2 and KIR
KIR expression as surrogate marker for clonality
Chronic lymphoproliferative
disorder of NK-cells
New provisional entity based on the need to
distinguish from aggressive NK-cell leukemia
Aggressive NK-cell leukemia Aggressive NK-cell leukemia
Adult T-cell leukemia/lymphoma Adult T-cell leukemia/lymphoma Diagnostic criteria for clinical subtypes
Neoplastic counterpart for CD4+CD25+FOXP3+
regulatory T-cells
Sezary syndrome Sezary syndrome Diagnostic criteria
New immunophenotypic markers, cutaneous
lymphocyte antigen+, skin-homing receptor
CCR4+, and lack CD7 and CD26
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by a persistent (>6 months duration) increase in peripheral
blood NK-cells (>2×109/L) without a clearly identified
cause. Reactive and neoplastic proliferations are difficult to
distinguish, and it is currently a provision entity within the
WHO classification. NK-cells are negative for surface CD3
but positive for cytoplasmic CD3ε (the antigen recognized
by the paraffin CD3 antibody); CD16 with weak CD56
expression is frequently observed. Markers of cytotoxic T-
cells such as TIA1, granzyme B, and granzyme M are
positive. The expression of CD2, CD7, and CD57 may be
diminished or absent while aberrant coexpression of CD5
and CD8 can be seen. Expression of the KIR family of NK-
cell receptors is either restricted to one isoform or
completely lacking. At the molecular level, there are no
rearrangements of the immunoglobulin and TCR genes.
The karyotype is normal in most cases. Clonality assays
have demonstrated that a subset of cases is clonal. EBV is
negative in contrast to aggressive NK-cell leukemia.
Aggressive NK-cell leukemia
Expression of Fas ligand by the neoplastic cells with
elevated levels in the serum is a new observation. Notably,
a clear distinction between aggressive NK-cell leukemia
and chronic lymphoproliferative disorders of NK-cells is
made in the current WHO classification.
Adult T-cell leukemia/lymphoma (ATLL)
The 2008 WHO classification provides a diagnostic criteria
for clinical subtypes of ATLL which is correlated with
clinical outcome. The three clinical subtypes are smolder-
ing, chronic, and acute. While four clinical variants are
recognized, diagnostic criteria for only three of these are
outlined in the updated classification. Furthermore, it is
unclear whether the terms “variants” and “subtypes” are
used interchangeably. The postulated normal counterpart
of ATLL is considered to be peripheral blood CD4+ T-
cells which show an immunophenotype closest to the
CD4+CD25+FOXP3+ regulatory T-cells.
Sezary syndrome (SS)
A distinct and separate section has been created to discuss
SS in the 2008 WHO classification. Diagnostic criteria for
SS are outlined which include the presence of one or more of
the following: an absolute Sezary cell count of at least 1,000
cells per mm3, an expanded CD4+ T-cell population resulting
in a CD4/CD8 ratio of more than 10, and/or loss of one or
more T-cell antigens. The immunophenotype of Sezary cells
is better defined in the updated classification. In addition to
CD2, CD3, CD4, and CD5, they express cutaneous
lymphocyte antigen (CLA) and the skin-homing receptor
CCR4 and lack CD7 and CD26. In addition, the expression
of T-plastin is greatly increased in Sezary cells relative to
normal helper T-cells. Recent studies using molecular
cytogenetic techniques such as M-FISH and comparative
genomic hybridization techniques have shown a high rate of
unbalanced translocations and associated deletions involving
chromosome 1p, 6q, 10q, 17p, and 19 suggesting the role of
genetic instability. Other molecular abnormalities include
inactivation of TP53, p16INK4a, and amplification of JUNB.
EBV-positive T-cell lymphoproliferative disorders
of childhood
In the 2008 WHO classification, two new major types of
EBV-associated T-cell lymphoproliferative disorders affect-
ing pediatric population have been incorporated: systemic
EBV-positive T-cell lymphoproliferative disease of child-
hood and hydroa vacciniforme-like lymphoma. Both of
them occur predominantly in Asians and in Native
Americans from Central and South America and Mexico.
Systemic EBV-positive T-cell lymphoproliferative disease of
childhood This is a life-threatening illness of children and
young adults characterized by a clonal proliferation of
EBV-infected T-cells with an activated cytotoxic phenotype.
It usually occurs shortly after primary acute EBV infection in
previously healthy patients or in the setting of chronic active
EBV infection (CAEBV). It has a rapid progression with
multiple organ failure, sepsis, and death, usually from days
to weeks. The most frequent sites of involvements are liver
and spleen followed by lymph nodes, bone marrow, skin, and
lung. The most typical phenotype of the tumor cells is
CD2+CD3+CD56− and positive for cytotoxic proteins.
Most cases secondary to acute primary EBV infection are
CD8+; whereas, cases in the setting of severe CAEBV
are CD4+. EBV is always positive. The tumor cells have
monoclonaly rearranged TCR genes.
Hydroa vacciniforme-like lymphoma This is an EBV-
positive cutaneous T-cell lymphoma (CTCL) occurring in
children and associated with sun sensitivity. This condition
affects primarily sun-exposed skin, in particular, the face.
These cases have usually a CD8+ cytotoxic phenotype. Most
cases have clonal rearrangement of the TCR genes. EBV-
encoded RNA (EBER) in situ hybridization is universally
positive, but LMP1 is generally negative. It is still not clear
whether severe mosquito-bite allergy, which is of NK
derivation and EBV-associated, is part of hydroa
vacciniforme-like lymphoma or a distinctive entity within
the spectrum of EBV-associated disorders. Both disorders
are considered part of the spectrum of severe CAEBV, with
a broad spectrum of clinical aggressiveness.
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T-cell and NK-cell neoplasms with extranodal
presentation
Extranodal T-cell and NK-cell neoplasms in the 2008 WHO
includes extranodal NK/T-cell lymphoma, nasal type; EATL;
hepatosplenic T-cell lymphoma; and SPTCL (Table 2).
Extranodal NK/T-cell lymphoma, nasal type
No significant changes have been made. The 2008 WHO
emphasizes that although extranodal NK/T-cell lymphoma,
nasal type occurs predominantly in the upper aerodigestive
tract, extranasal involvement is not infrequent (extranasal
NK/T-cell lymphomas), and both presentations are EBV-
associated. By definition, the neoplastic cells show CD56
expression and cytoplasmic CD3ε with negative surface
CD3, although in rare cases, CD56 might be weak or even
negative. EBER is positive virtually in every neoplastic cell
and is a prerequisite for the diagnosis. LMP1 is often
negative. Cytotoxic molecules (granzyme B, perforin, and
TIA1) are positive. Other T- and NK-cell markers such as
CD4, CD5, CD2, CD16, CD57, CD43, CD45RO, TCRγ,
and βF1 are negative. Occasional cases are positive for
CD8, CD7, or CD30. Recent comparative genomic hybrid-
ization studies showed some recurrent chromosomal alter-
ations. A proportion of cases have partial deletion of FAS
gene, mutations of TP53, β-catenin, K-RAS, or C-KIT gene,
but the significance of all these alterations is still unclear. It
is important to consider in the differential diagnosis a
spectrum of EBV-associated T-cell or NK-cell lymphopro-
liferative disorders, including CAEBV, and the new
recognized group of systemic EBV+ T-cell lymphoprolifer-
ative disease of childhood.
Enteropathy-associated T-cell lymphoma (EATL)
The most important changes in the 2008 WHO classifica-
tion are the recognition of two different types of EATL and
its genetic changes. EATL-classical form is the most
frequent type (80–90%) and is associated with celiac
disease. The degree of associated enteropathy is highly
variable; some patients have a long history of celiac
disease, and some are diagnosed in the same episode in
which the lymphoma is diagnosed. Although the cytolog-
ical appearance is variable, most cases are composed of
large lymphoid cells often with an inflammatory back-
ground. The immunophenotype of the tumor cells is CD3+,
CD5−, CD7+, CD8− (20%+), CD4−, CD103+, TCRβ+/−,
contains cytotoxic granules-associated proteins and, in
almost all cases, a proportion of the tumor cells express
CD30. The intraepithelial lymphocytes (IEL) in the
adjacent enteropathic mucosa may show an abnormal
phenotype, usually CD3+, CD5−, CD8−, and CD4−.
EATL-type II or monomorphic type represents 10–20% of
all EATL cases. This variant may occur sporadically, without
risk factors for celiac disease, suggesting that the monomor-
phic variant represents a distinct disease entity. This variant
is composed of monomorphic medium-sized cells with a
distinctive immunophenotype. The tumor cells are CD3+,
CD4−, CD8+, CD56+, and TCRβ+. Interestingly, both
forms of EATL are characterized by complex segmental
amplifications of the 9q31.3-qter chromosome region in 58–
70% of the cases or by deletions in 16q12.1. Additionally,
the classical form of EATL shows chromosomal gains in 1q
and 5q; whereas, the monomorphic variant has 8q24 (MYC)
amplifications. Importantly, both classical EATL and the
monomorphic form have a similar clinical course.
Table 2 Summary of the categories of T-cell and NK-cell neoplasms with a predominant extranodal presentation within the 2001 and 2008 WHO
classification






Enteropathy-associated T-cell lymphoma Enteropathy-associated
T-cell lymphoma (EATL)
Two forms are recognized: EATL-classical form is associated
to celiac disease, CD3+,CD4−, CD8−, and CD56− and
EATL-type II or monomorphic type, CD8+, CD56+, and CD4−
Common genetic alterations: amplification of 9q31.3 or deletion
of 16q21
Precursor lesions are recognized EATL in situ/intraepithelial
T-cell lymphoma





Includes only the α/β type
Twenty percent associated to autoimmune disease, mostly
systemic lupus erythematosus
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The 2008 WHO classification emphasizes that refractory
celiac disease (RCD) in which the IEL show downregulation of
CD8 and monoclonal T-cell rearrangements, which usually is
the same monoclonal TCR gene rearrangement as the subse-
quent developed T-cell lymphoma, represents most probably a
precursor lesion and, therefore, can be considered as examples
of intraepithelial T-cell lymphoma or EATL in situ. The
monomorphic form of EATL may also be preceded by RCD
in which the IEL immunophenotype is similar to the neoplastic
cells of the subsequent lymphoma, namely, CD8+CD56+.
Hepatosplenic T-cell lymphoma (HSTL)
No significant changes have been made. Aberrant expression
of multiple KIR isoforms along with dim or absent CD94 is a
new observation. The 2008 WHO classification stresses the
fact that 20% of HSTL arise in the setting of chronic
immunosuppression, most commonly after solid organ
transplantation, however, may also occur in children treated
with azathioprine and infliximab for Crohn’s disease.
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL)
The most important change in the 2008 WHO classification
is that the cases expressing γδ TCR are excluded from
SPTCL and are now reclassified as primary cutaneous γδ
T-cell lymphoma (see below). The new 2008 WHO
classification also emphasizes the association of SPTCL
with autoimmune disorders that can be found in up to 20%
of the cases. The most frequent association is with systemic
lupus erythematosus. Furthermore, SPTCL may show
overlapping features with lupus profundus panniculitis.
The immunophenotype is of a mature αβ T-cell with
expression of CD8, cytotoxic associated proteins, and βF1.
In contrast to cutaneous γδ T-cell lymphoma, the tumor
cells in SPTCL do not express CD56, hemophagocytic
syndrome is seen only in 15–20% of the cases, and SPTCL
has a much better prognosis. EBV virus is always absent.
T-cell neoplasms with nodal presentation
Mature T-cell neoplasms with a predominantly nodal
presentation include the following entities: AITL; anaplastic
large cell lymphoma (ALCL), ALK-positive; ALCL, ALK-
negative; and peripheral T-cell lymphoma (PTCL), not
otherwise specified (NOS; Table 3).
Angioimmunoblastic T-cell lymphoma (AITL)
The most significant advances in respect with this disease
entity are (1) the demonstration of CD10 expression by at least
a fraction of the neoplastic cells, in most cases, a feature very
helpful for diagnostic purposes, and (2) the recent identifica-
tion of the cellular origin of the neoplastic T-cell of AITL.
Several studies have indeed provided convergent evidence
that AITL tumor cells have immunophenotypic and molecular
features overlapping with those of a specific subset of CD4+
helper T-cells, namely, TFH, normally located in the light
zone of germinal centers where they exert a functional help for
follicular B-cell differentiation. This specific cellular deriva-
tion likely explains several of the peculiar patholobiological
features inherent to this disease, for example, the expansion of
B-cells and hypergammaglobulinemia and the striking prolif-
eration of follicular dendritic cells. Moreover, importantly,
several phenotypic markers of normal TFH cells including the
CXCL13 chemokine and program death-1 (PD-1, a member
of the CD28 costimulatory membrane receptor family) have
been validated in AITL neoplastic cells and represent novel
diagnostic markers for the identification of AITL tumor cells
in lymph nodes and in cases of extranodal dissemination of the
disease.
Table 3 Summary of the categories of T-cell neoplasms with a predominantly nodal presentation, as listed in the 2001 and 2008 WHO
classifications
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Anaplastic large cell lymphoma,
ALK-positive (ALCL, ALK+)
Distinct disease entity in the 2008 WHO classification
Morphologic variants: addition of the Hodgkin-like pattern
Anaplastic large cell lymphoma,
ALK-negative (ALCL, ALK−)
New provisional entity based on need to distinguish from ALCL ALK+
Peripheral T-cell lymphoma,
unspecified (PTCL-u)
Peripheral T-cell lymphoma, not
otherwise specified (PTCL, NOS)
Minor change in designation (“unspecified” to “not otherwise specified”)
Three variants are recognized: lymphoepithelioid variant, the T-zone
variant (both already listed in 2001), and the follicular variant
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Anaplastic large cell lymphoma, ALK-positive
(ALCL, ALK+)
The definition of ALCL remains that of a T-cell lymphoma
composed of large cells with abundant cytoplasm and
pleomorphic horseshoe-shaped nuclei including a propor-
tion of so-called “hallmark cells” (with a paranuclear
eosinophilic region) and characterized by strong CD30
expression. The major change introduced in the 2008 WHO
classification is the segregation of systemic ALCL into two
separate entities depending on the presence or absence of
ALK gene rearrangement and upregulation of ALK protein.
In the 2001 WHO classification, both ALK-positive and
ALK-negative ALCL were considered as two variants of
the same entity. ALCL, ALK-positive represents a well-
delineated entity defined by a characteristic genetic alter-
ation consisting of rearrangement of the ALK gene.
Remarkably, this entity is associated with an overall good
prognosis, superior to that of any other nodal T-cell
lymphoma entity. The morphologic spectrum of ALK-
positive ALCL is broad and has been expanded to include
the recently described “Hodgkin-like” pattern, mimicking
nodular sclerosis Hodgkin lymphoma. The lymphohistiocytic
and small cell patterns, which are the most common
morphologic variants, tend to be associated with a lesser
favorable outcome. Conversely, the genetic heterogeneity of
ALK translocations (to various partner genes), which dictates
the subcellular distribution of ALK fusion proteins, bears no
correlation with the clinical features nor with the morphology.
Anaplastic large cell lymphoma, ALK-negative
(ALCL, ALK−)
ALCL, ALK-negative is introduced in the 2008 WHO
classification as a provisional entity. It is defined as a
CD30+ large cell neoplasm that by morphology is
indistinguishable from the common pattern of ALCL,
ALK-positive (i.e., contains hallmark cells) but lacks
ALK gene rearrangement and is negative for ALK protein
expression. Other immunophenotypic features are similar to
those of ALCL, ALK-positive, but the expression of pan-T-
cell antigens tends to be more frequent, while the
expression of cytotoxic markers and of epithelial membrane
antigen (EMA) is less common. As the morphological
variants of ALCL cannot reliably be identified without
ALK expression, ALK-negative ALCL comprises exclu-
sively cases with classical morphology. As the defining
criteria of this entity are in part subject to inter-observer
variability, the borders of this entity are not well defined, and
in particular, there is some overlap with a subset of PTCL,
NOS showing CD30 expression. Clinically, ALCL, ALK-
negative has a prognosis much worse than ALK-positive
ALCL but an outcome superior to that of PTCL, NOS.
Peripheral T-cell lymphoma, not otherwise specified
(PTCL, NOS)
The category of the PTCL, unspecified (PTCL-u) in the
2001 WHO classification is now designated as “PTCL, not
otherwise specified” (PTCL, NOS), an appellation reflect-
ing the expectations for better specification or subdivi-
sions in the future. This category defined by exclusion
encompasses all mature T-cell neoplasms lacking specific
features that would allow categorization within any of the
better-defined “specific” subtypes of PTCL described in
the WHO classification. PTCL, NOS often affects lymph
nodes, but presentation in extranodal sites, such as the
skin, is also frequently encountered.
The two variants of PTCL, NOS listed in the 2001 WHO
classification are maintained in the 2008 WHO edition, i.e.,
the lymphoepithelioid variant, also known as Lennert’s
lymphoma, which is derived from CD8+ T-cells in most
instances and the T-zone variant, characterized by a
perifollicular growth pattern and a small cell morphology,
both of which may be associated with a more indolent
clinical course. A third variant more recently described—
follicular PTCL—has been added to the current classifica-
tion. This peculiar and rare form of PTCL, NOS refers to a
pattern of growth intimately related to follicular struc-
tures, which may mimic follicular lymphoma, exhibit
features suggestive of marginal zone lymphomas or
involve mantle zones. Interestingly, follicular PTCL
exhibits a TFH phenotype, questioning its possible
relationship to AITL.
T-cell neoplasms with cutaneous presentation
Cutaneous T-cell lymphomas (CTCLs) in the 2008 WHO
include the following entities: MF; SS; primary cutaneous
CD30-positive T-cell lymphoproliferative disorders, includ-
ing primary cutaneous ALCL and lymphomatoid papulosis
(LyP); and the new group of primary cutaneous PTCLs,
rare subtypes, which includes primary cutaneous gamma-
delta T-cell lymphoma (PCGD-TCL), primary cutaneous
CD8-positive aggressive epidermotropic cytotoxic T-cell
lymphoma, and primary cutaneous CD4-positive small/
medium T-cell lymphoma. A disease that was previously
considered to be of NK-derivation, the blastic NK-cell
lymphoma, has changed its name to blastic plasmacytoid
dendritic cell neoplasm (BPDC), and it is now classified
within the myeloid neoplasms (Table 4).
Mycosis fungoides (MF)
The most significant changes in this disease are the
defining criteria for clinical staging and the histopatho-
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logical staging for “clinically abnormal” lymph nodes.
The purpose of revising the staging and classification
system was to incorporate all the steady advances in the
areas of molecular biology, immunohistochemistry, and
imaging as well as new data on prognostic variables in
MF. The updated International Society for Cutaneous
Lymphomas/European Organization of Research and Treat-
ment of Cancer (ISCL/EORTC) revision to the N (node)
classification was incorporated into the 2008 WHO
classification. This staging system incorporated the previ-
ous National Cancer Institute and Dutch lymph node
staging systems. This classification eliminates biopsies of
lymph nodes for staging purposes, unless they are “clinically
abnormal”. The definition of “clinically abnormal” lymph
nodes refers to lymph nodes larger than 1.5 cm. There are
three categories recognized. The N1 category includes
dermatopathic lymphadenopathy and the presence of occa-
sional atypical lymphocytes with clusters of three to six cells.
The N2 category includes dermatopathic lymphadenopathy
with early involvement with scattered atypical cerebriform
mononuclear cells, defined as cells with diameter larger than
7.5 μm. The architecture here is still preserved. The N3
category includes overt involvement of the lymph nodes
with both, partial, or complete architecture effacement. N3
lymph nodes may simulate PTCLs, NOS or Hodgkin
lymphoma.
The clinical staging system was better defined. Stage I
includes disease confined to the skin with patches, papules,
and or plaques with no “clinically abnormal” lymph nodes
(<10% skin surface, stage IA; >10%, stage IB). Stage II
includes skin involvement associated with early (N1-N2)
lymph node involvement (stage IIA) or one or more skin
tumors (>1 cm, stage IIB). Stage III includes skin
involvement with erythroderma, N1-N2 lymph node in-
volvement, and absent or low blood tumor burden (<1,000/
ml circulating Sezary cells). Stage IV includes high blood
tumor burden (>1,000/ml circulating Sezary cells) and/or
extensive lymph node involvement (N3) or visceral
involvement.
New studies have identified the constitutive activation of
the transcription factor STAT3 and the inactivation of
CDK2A/p16ink4 and PTEN. Both changes might be
Table 4 Summary of the category of T-cell lymphomas with a predominant cutaneous involvement within the 2001 and 2008 WHO classification
2001 WHO classification 2008 WHO classification Comments
Mycosis fungoides Mycosis fungoides Better-defined staging system
Constitutive activation of Stat3
TNF in the tumorigenesis of MF
CD8+ in pediatric MF
Sezary syndrome Sezary syndrome Better-defined diagnostic criteria
New immunophenotypic markers, cutaneous
lymphocyte antigen+, skin-homing receptor
CCR4+, and lack CD7 and CD26
Primary cutaneous anaplastic large
cell lymphoma (C-ALCL)
Primary cutaneous anaplastic
large cell lymphoma (C-ALCL)
Rare cases CD8+
Rare coexpression of CD56+
Lymphomatoid papulosis Lymphomatoid papulosis Three histologic subtypes are recognized (A, B, and C)
Rare cases of CD8+ and NK phenotype
Subcutaneous panniculitis-like




Three histologic patterns: epidermotropic, dermal,
and subcutaneous
CD3+, CD56+TCRδ+ and EBV negative CD4−,CD8−,
and βF1−




Disseminates to visceral sites
Cell of origin: CD8+ cytotoxic T-cell of α/β subtype
Aggressive disease
Primary cutaneous CD4+ small/medium
T-cell lymphoma
Provisional entity
Solitary skin lesion on the head and neck
Cell of origin: skin-homing CD4+ T-cell
Favorable prognosis
Blastic NK-cell lymphoma Blastic plasmocytoid dendritic
cell neoplasm
Included now with myeloid neoplasias
CD56+TdT+ CD4, CD43, TCL1, and CD123
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associated with disease progression. New gene expression
profiling studies have shown tumor necrosis factor (TNF)
anti-apoptotic pathway activation in the tumorigenesis of
MF. Interestingly, a CD8+ MF has been incorporated in the
2008 WHO, which has been reported more commonly in
pediatric population.
Primary cutaneous CD30-positive T-cell
lymphoproliferative disorders
Primary cutaneous CD30+ lymphoproliferative disorders
are the second most common group of CTCLs, account-
ing for approximately 30% of the cases. This group
includes primary cutaneous (C)-ALCL, LyP, and border-
line cases.
Primary cutaneous anaplastic large cell lymphoma (C-
ALCL) No significant changes have been made. The 2008
WHO classification emphasizes the role of immunopheno-
type to differentiate cutaneous and systemic ALCL. C-
ALCL neoplastic cells show an activated CD4+ T-cell
phenotype with frequent expression of cytotoxic proteins.
It is important to highlight that some cases (<5%) have a
CD8+ T-cell phenotype. Unlike systemic ALCL, most C-
ALCLs express the CLA but do not express EMA or ALK.
Coexpression of CD56 is rarely observed, and its expression
is not associated with unfavorable prognosis.
Lymphomatoid papulosis (LyP) No significant changes
have been made. The 2008 WHO classification recog-
nizes three histological subtypes (Types A, B, and C),
which represent a spectrum of the disease with over-
lapping features. The type A and B lesions remained as
previously defined. The type C lesions are composed of
a monotonous population or large clusters of large CD30-
positive T-cells with relative few admixed inflammatory
cells. The immunophenotype of Type A and C lesions is
identical to the tumor cells in C-ALCL. The tumor cells
in LyP type B lesions have a CD3+, CD4+, CD8−
phenotype and do not express CD30 antigen. Importantly,
rare cases of LyP have been reported to have a CD8+ or
an NK-cell phenotype.
Primary cutaneous peripheral T-cell lymphomas, rare
subtypes
This group is composed of three new entities in the 2008
WHO classification, two of them are still considered as
provisional entities.
Primary cutaneous gamma-delta T-cell lymphoma These
cases were included in the previous WHO classification in
the group of SPTCL with a gamma/delta phenotype.
However, due to the extensive involvement of the subcu-
taneous tissue, as well as the dermis and epidermis, these
cases are now classified in the 2008 WHO classification as
part of the primary cutaneous PTCLs. PCGD-TCL is a
lymphoma composed of a clonal proliferation of mature,
activated γ/δ T-cells with a cytotoxic phenotype. Three
major histologic patterns of skin involvement are recog-
nized: epidermotropic, dermal, and predominantly subcuta-
neous. Often more than one histologic pattern is observed
in the same skin biopsy. A hemophagocytic syndrome
commonly occurs in patients with panniculitis-like tumors.
Importantly, apoptosis and necrosis are common, often with
angioinvasion. The tumor cells show a mature activated γ/δ
cytotoxic T-cell phenotype with CD3+CD2+CD56+ and are
negative for βF1, CD4, and usually CD8. The neoplastic
cells show clonal rearrangement of TCRγ and TCRδ genes,
and EBV is negative. Patients with subcutaneous fat
involvement tend to have a poor prognosis. An issue still
not resolved is whether cutaneous and mucosal γ/δ TCL
are part of the same disease.
Primary cutaneous CD8-positive aggressive epidermo-
tropic cytotoxic T-cell lymphoma This is a new provisional
entity in the 2008 WHO classification. This CTCL is
characterized by a proliferation of epidermotropic CD8+
cytotoxic T-cells and a very aggressive clinical behavior.
Patients present with disseminated eruptive papules, nod-
ules, and tumors showing central ulceration and necrosis.
One important feature of this CTCL is its unusual
dissemination to visceral sites (lung, testis, central nervous
system, and oral mucosa) without spreading to the lymph
nodes. The tumor cells have a βF1+, CD3+, CD8+, and
cytotoxic proteins+ phenotype, with frequent loss of other
T-cell antigens (CD2, CD5, CD7, and CD45RO). EBV is
negative. The neoplastic cells show clonal TCR gene
rearrangements, and specific genetic abnormalities have
not been described.
Primary cutaneous CD4-positive small/medium T-cell lym-
phoma This is a new provisional entity in the 2008 WHO
classification. This CTCL is characterized by a predomi-
nance of small to medium-sized CD4+ pleomorphic T-cells
without features of MF and a very good prognosis. Most of
the cases present as a solitary skin lesion. The lesions present
usually on the head, neck, or upper trunk. By definition,
these lymphomas have a CD3+, CD4+, CD8−, and CD30−
phenotype, sometimes with loss of pan-T-cell markers.
Cytotoxic proteins are not expressed. Of note is that these
lymphomas might show admixed plasma cells and B-cells,
making the differential diagnosis from a reactive process
difficult. However, the loss of pan-T-cell markers and/or
clonal rearrangement of TCR genes are very useful criteria
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for the differential diagnosis. EBV is negative. No specific
genetic abnormalities have been described.
Blastic plasmocytoid dendritic cell neoplasm
The last disease to be briefly mentioned herein is blastic
plasmocytoid dendritic cell neoplasm. In the previous
WHO classification, this entity was known as blastic
NK-cell lymphoma. Blastic NK-cell lymphoma was
described as a clinically aggressive neoplasm with a
high incidence of cutaneous involvement and risk of
leukemic dissemination. The blastic cytologic appearance
and the CD56 expression initially suggested an NK-
precursor origin. However, recent molecular and immu-
nohistochemical studies suggested that these tumors
derived from a plasmocytoid dendritic cell precursor.
Therefore, it was decided in the 2008 WHO to rename
this entity and to include it in the group of myeloid
neoplasias. The BPDC is a rare hematologic neoplasm with
a predilection for the skin, followed by bone marrow and
peripheral blood. Tumor cells express CD4, CD43, CD56,
TCL1, and CD123. TdT is positive in a third of the cases.
Because other CTCL may express CD4 and CD56, it is
mandatory to perform an extensive immunohistochemical
analysis before a definitive diagnosis of BPDC is made.
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